Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Net Margin for 7 consecutive years, with 16769.7% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin fell 1054881.0% year-over-year to 16769.7%; the TTM value through Mar 2026 reached 153923.53%, down 15349618.0%, while the annual FY2024 figure was 408.73%, 874925.0% up from the prior year.
  • Net Margin hit 16769.7% in Q1 2026 for Barinthus Biotherapeutics, up from 2112600.0% in the prior quarter.
  • Across five years, Net Margin topped out at 133.35% in Q3 2022 and bottomed at 2112600.0% in Q2 2025.
  • Average Net Margin over 5 years is 214675.69%, with a median of 2110.78% recorded in 2023.
  • On a YoY basis, Net Margin climbed as much as 4825480bps in 2022 and fell as far as -167212775bps in 2022.
  • Barinthus Biotherapeutics' Net Margin stood at 327.75% in 2022, then plummeted by -2076bps to 7132.93% in 2023, then soared by 99bps to 54.31% in 2024, then crashed by -3890109bps to 2112600.0% in 2025, then skyrocketed by 99bps to 16769.7% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 16769.7%, 2112600.0%, and 6220.89% for Q1 2026, Q2 2025, and Q1 2025 respectively.